Objective:To determine the effects of inflammatory mediators on the production of activin A, inhibin A, and the binding protein follistatin in term amnion and chroidecidual tissues.
Methods:The effects of interleukin-1β (IL-1β; 1 ng/mL), tumor necrosis factor-α (TNF-α; 10 ng/mL), and bacterial lipopolysaccharide (LSP; 5 μg/mL) on production rates of activin A, inhibin A, and follistatin by term choriodecidual and amnion membranes in explant culture were determined using specific enzyme-linked immunoabsorbent assays.
Results:All explants (n = 6 placentas) produced detectable amounts of activin A, inhibin A, and follistatin under basal conditions; choriodecidual production rates were more than tenfold higher than amnion rates. In amnion explants, activin A production was stimulated by IL-1β and TNF-α to 450 ± 155.4% and 531 ± 170.8% of control, respectively (mean ± standard error of the mean; P < .05 by analysis of variance), whereas production of inhibition and follistatin was stimulated to a much more modest extent. Similar responses were observed in the choriodecidual explants. Lipopolysaccharide had no significant effect on amnion activin A production, but stimulated choriodecidual production to 290 ± 34% of control. Lipopolysaccharide exerted only limited effects on inhibin A and follistatin production.
Conclusions:Treatment with proinflammatory mediators resulted in a preferential increase in activin A production compared with that of inhibin A or follistatin. These findings suggest that inflammation of the gestational membranes could result in increased local activin. A production and bioactivity.
1. de Krester DM. Inhibin, activin and follistatin: Placental production and physiology. In: Rice GE, Brennecke SP, eds. Molecular aspects of placental and fetal membrane autacoids. Boca Raton, Florida: CRC Press, 1993:239-250.
2.
2. Massague J. The transforming growth factor-beta family. Annu Rev Cell Biol1990;6:597-641.
3.
3. Petraglia F, Gallinelli A, Grande A, et al. Local production and action of follistatin in human placenta. J Clin Endocrinol Metab1994;78:205-210.
4.
4. de Krester DM, Foulds LM, Hancock M, Robertson DM. Partial characterization of inhibin, activin, and follistatin in the term human placenta. J Clin Endocrinol Metab1994;79:502-507.
5.
5. Loveland KL, McFarlane JR, de Krester DM. Expression of activin beta C subunit mRNA in reproductive tissues. J Mol Endocrinol1996;17:61-65.
6.
6. Petraglia F. Inhibin, activin and follistatin in the human placenta—a new family of regulatory proteins. Placenta1997;18:3-8.
7.
7. Minami S, Yamoto M, Nakano R. Immunohistochemical localization of inhibin/activin subunits in human placenta. Obstet Gynecol1992;80:410-414.
8.
8. Petraglia F, Calza L, Garuti GC, et al. Presence and synthesis of inhibin subunits in human decidua. J. Clin Endocrinol Metab1990;71:487-492.
9.
9. Petraglia F, Garuti GC, Calza L, et al. Inhibin subunits in human placenta: Localization and messenger ribonucleic acid levels during pregnancy. Am J Obstet Gynecol1991;165:750-758.
10.
10. Keelan JA, Groome NP, Mitchell MD. Regulation of activin-A production by human amnion, decidua and placenta in vitro by pro-inflammatory cytokines. Placenta1998;19:429-434.
11.
11. Riley SC, Leask R, Balfour C, Brennand JE, Groome NP. Production of inhibin forms by the fetal membranes, decidua, placenta and fetus at parturition. Hum Reprod2000;15:578-583.
12.
12. Yohkaichiya T, Polson D, O'Connor A, et al. Concentrations of immunoactive inhibin in serum during human pregnancy: Evidence for an ovarian contribution. Reprod Fertil Dev1991;3:671-678.
13.
13. Muttukrishna S, Fowler PA, George L, Groome NP, Knight PG. Changes in peripheral serum levels of total activin A during the human menstrual cycle and pregnancy. J Clin Endocrinol Metab1996;81:3328-3334.
14.
14. Wallace EM, Riley SC, Crossley JA, et al. Dimeric inhibins in amniotic fluid, maternal serum, and fetal serum in human pregnancy. J Clin Endocrinol Metab1997;82:218-222.
15.
15. Fowler PA, Evans LW, Groome NP, Templeton A, Knight PG. A longitudinal study of maternal serum inhibin-A, inhibin-B, activin-A, activin-AB, pro-alpha C and follistatin during pregnancy. Hum Reprod1998;13:3530-3536.
16.
16. O'Connor AE, McFarlane JR, Hayward S, Yohkaichiya T, Groome NP, de Kretser DM. Serum activin A and follistatin concentrations during human pregnancy: A cross-sectional and longitudinal study. Hum Reprod1999;14:827-832.
17.
17. Petraglia F, Gallinelli A, De Vita D, Lewis K, Mathews L, Vale W. Activin at parturition: Changes of maternal serum levels and evidence for binding sites in placenta and fetal membranes. Obstet Gynecol1994;84:278-282.
18.
18. Petraglia F, Garg S, Florio P, et al. Activin A and activin B measured in maternal serum, cord blood serum and amniotic fluid during pregnancy. Endocr J1993;1:323-327.
19.
19. Esch FS, Shimasaki S, Mercado M, et al. Structural characterization of follistatin: A novel follicle-stimulating hormone release-inhibiting polypeptide from the gonad. Mol Endocrinol1987;1:849-855.
20.
20. Inouye S, Guo Y, DePaolo L, Shimonaka M, Ling N, Shimasaki S. Recombinant expression of human follistatin with 315 and 288 amino acids: Chemical and biological comparison with native porcine follistatin. Endocrinology1991;129:815-822.
21.
21. Shimasaki, S, Koga M, Esch F, et al. Porcine follistatin gene structure supports two forms of mature follistatin produced by alternative splicing. Biochem Biophys Res Commun1988;152:717-723.
22.
22. Evans LW, Muttukrishna S, Groome NP. Development, validation and application of an ultra-sensitive two-site enzyme immunoassay for human follistatin. J Endocrinol1998;156:275-282.
23.
23. Yokoyama Y, Nakamura T, Nakamura R, Irahara M, Aono T, Sugino H. Identification ofactivins and follistatin proteins in human follicular fluid and placenta. J Clin Endocrinol Metab1995;80:915-921.
24.
24. de Winter JP, Ten Dijke P, de Vries CJM, et al. Follistatin neutralizes activin bioactivity by inhibition of activin binding to its type II receptors. Mol Cell Endocrinol1996;116:105-114.
25.
25. Fowler PA, Evans LW, Groome NP, Templeton A, Knight PG. A longitudinal study of maternal serum inhibin-A, inhibin-B, activin-A, activin-AB, pro-alpha C and follistatin during pregnancy. Hum Reprod1998;13:3530-3536.
26.
26. Wakatsuki M, Shintani Y, Abe M, Liu ZH, Shitsukawa K, Saito S. Immunoradiometric assay for follistatin: Serum immunoreactive follistatin levels in normal adults and pregnant women. J Clin Endocrinol Metab1996;81:630-634.
27.
27. Woodruff TK, Sluss P, Wang E, Janssen I, Mersol-Barg MS. Activin A and follistatin are dynamically regulated during human pregnancy. J Endocrinol1997;152:167-174.
28.
28. Keelan JA, Zhou RL, Mitchell MD. Activin A exerts both pro- and anti-inflammatory effects on human term gestational tissues. Placenta2000;21:38-43.
29.
29. Song Y, Keelan J, France JT. Activin-A stimulates, while transforming growth factor beta 1 inhibits, chorionic gonadotrophin production and aromatase activity in cultured human placental trophoblasts. Placenta1996;17:603-610.
30.
30. Florio P, Lombardo M, Gallo R, et al. Activin A, corticotropin-releasing factor and prostaglandin F2 alpha increase immunoreactive oxytocin release from cultured human placental cells. Placenta1996;17:307-311.
31.
31. Toth P, Li X, Lei ZM, Rao CV. Expression of human chorionic gonadotropin (hCG) luteinizing hormone receptors and regulation of the cyclooxygenase-1 gene exogenous hCG in human fetal membranes. J Clin Endocrinol Metab1996;81:1283-1288.
32.
32. Takahashi S, Uchimaru K, Harigaya K, Asano S, Yamashita T. Tumor necrosis factor and interleukin-1 induce activin A gene expression in a human bone marrow stromal cell line. Biochem Biophys Res Comm1992;188:310-317.
33.
33. Shao L, Frigon NL Jr, Sehy DW, et al. Regulation of production of activin A in human marrow stromal cells and monocytes. Exp Hematol1992;20:1235-1242.
34.
34. Yu J, Shao LE, Frigon NL Jr, Lofgren J, Schwall R. Induced expression of the new cytokine, activin A, in human monocytes: Inhibition by glucocorticoids and retinoic acid. Immunology1996;88:368-374.
35.
35. Yu EW, Dolter KE, Shao LE, Yu J. Suppression of IL-6 biological activities by activin A and implications for inflammatory arthropathies. Clin Exp Immunol1998;112:126-132.
36.
36. Nusing RM, Barsig J. Inflammatory potency of activin A. Effect on prostanoid and nitric oxide formation. Adv Exp Med Biol1997;407:243-248.
37.
37. Nusing RM, Barsig J. Induction of prostanoid, nitric oxide, and cytokine formation in rat bone marrow derived macrophages by activin A. Br J Pharmacol1999;127:919-926.
38.
38. de Krester DM, Hedger MP, Phillips DJ. Activin A and follistatin: Their role in the acute phase reaction and inflammatory. J Endocrinol1999;161:195-198.
39.
39. Hubner G, Brauchle M, Gregor M, Werner S. Activin A: A novel player and inflammatory marker in inflammatory bowel disease?Lab Invest1997;77:311-318.
40.
40. Petraglia F, De Vita d, Gallinelli A, et al. Abnormal concentration of maternal serum activin-A in gestational diseases. J Clin Endocrinol Metab1995;80:558-561.
41.
41. Keelan JA, Coleman M, Mitchell MD. The molecular mechanisms of term and preterm labor: Recent progress and clinical implications. Clin Obstet Gynecol1997;40:460-478.
42.
42. Dudley DJ, Trautman MS. Infection, inflammation, and contractions: The role of cytokines in the pathophysiology of preterm labour. Semin Reprod Endocrinol1994;12:263-272.
43.
43. Romero R, Munoz H, Gomez R, et al. Does infection cause premature labour and delivery?Semin Reprod Endocrinol1994;12:227-239.
44.
44. Simpson KL, Keelan JA, Mitchell MD. Labor-associated changes in interleukin-10 production and its regulation by immuno-modulators in human choriodecidua. J Clin Endocrinol Metab1998;83:4332-4337.
45.
45. Simpson KL, Keelan JA, Mitchell MD. Labour-associated changes in the regulation of production of immunomodulators in human amnion by glucocorticoids, bacterial lipopolysaccharide and proinflammatory cytokines. J Reprod Fertil1999;116:321-327.
46.
46. Keelan JA, Marvin KW, Sato TA, et al. Concentrations of activin A, inhibin A and follistatin in human amnion, choriodecidual and placental tissues at term and preterm. J Endocrinol1999;163:99-106.
47.
47. Muttukrishna S, Chamberlain P, Evans LW, Asselin J, Groome NP, Ledger WL. Amniotic fluid concentrations of dimeric inhibins, activin A and follistatin in pregnancy. Eur J Endocrinol1999;140:420-424.
48.
48. Knight PG. Roles of inhibins, activins, and follistatin in the female reproductive system. Front Neuroendocrinol1996;17:476-509.
49.
49. Petraglia F, Vaughan J, Vale W. Inhibin and activin modulate the release of gonadotropin-releasing hormone, human chorionic gonadotropin, and progesterone from cultured human placental cells. Proc Natl Acad Sci U S A1989;86:5114-5117.
50.
50. Caniggia I, Lye SJ, Cross JC. Activin is a local regulator of human cytotrophoblast cell differentiation. Endocrinology1997;138:3976-3986.
51.
51. Draper LB, Chong H, Wang E, Woodruff TK. The uterine myometrium is a target for increased levels of activin A during pregnancy. Endocrinology1997;138:3042-3026.
52.
52. Yu J, Dolter KE. Production of activin A and its roles in inflammation and hematopoiesis. Cytokines Cell Mol Ther1997;3:169-177.
